Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
NCT02626364
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
11
Enrollment
INDUSTRY
Sponsor class
Conditions
Recurrent/Refractory Glioblastoma
Interventions
DRUG:
crenolanib
Sponsor
Arog Pharmaceuticals, Inc.